Mealey's (February 18, 2020, 1:25 PM EST) -- WASHINGTON, D.C. — A petition to stay a mandate by the Federal Circuit U.S. Court of Appeals in a dispute over the patentability of genetically modified insulin was granted Feb. 10 by the U.S. Supreme Court, but just four days later, on Feb. 14, the order was vacated and the stay denied “in all respects,” according to the court docket (Sanofi-Aventis Deutschland GMBH v. Mylan Pharmaceuticals Inc., No. 19A886, U.S. Sup.)....